Next-generation sequencing (NGS) has become a cornerstone of precision oncology, enabling comprehensive genomic profiling that guides diagnosis, prognostication, and therapeutic selection.
This article provides a comprehensive guide for researchers and drug development professionals seeking to optimize coverage uniformity in targeted next-generation sequencing (NGS).
The integration of next-generation sequencing (NGS) into clinical practice and drug development research is fraught with complex bioinformatics challenges that impact data accuracy, reproducibility, and clinical utility.
Formalin-fixed paraffin-embedded (FFPE) samples are invaluable for biomedical research, yet their degraded, low-input DNA poses significant challenges for next-generation sequencing (NGS).
Next-generation sequencing (NGS) has revolutionized genetic research and clinical diagnostics, yet false positive variant calls remain a significant challenge that can misdirect research and clinical决策.
Next-generation sequencing (NGS) has revolutionized the identification of therapy resistance mechanisms, enabling more precise and personalized cancer treatment.
This article provides a comprehensive overview of the liquid biopsy workflow for cancer monitoring, tailored for researchers and drug development professionals.
This article provides researchers, scientists, and drug development professionals with a comprehensive framework for next-generation sequencing (NGS) variant calling pipelines.
The molecular complexity of cancer demands a systems-level approach that moves beyond single-omics analyses.
Next-generation sequencing (NGS) has revolutionized minimal residual disease (MRD) monitoring in hematologic malignancies, offering unprecedented sensitivity down to 10^-6 and the unique ability to track clonal evolution.